|
|
|
August 12, 2004
METABASIS ANNOUNCES SECOND QUARTER
2004 FINANCIAL RESULTS
August 3, 2004
METABASIS ANNOUNCES INITIATION OF
A MULTI-CENTER PHASE 2 CLINICAL TRIAL OF REMOFOVIR FOR THE TREATMENT
OF HEPATITIS B
July 27, 2004
METABASIS TO HOST CONFERENCE CALL
AND LIVE WEBCAST TO DISCUSS SECOND QUARTER 2004 FINANCIAL RESULTS
July 26, 2004
METABASIS ANNOUNCES ISSUANCE OF
A KEY PATENT COVERING ITS HEPDIRECT™
LIVER TARGETING PRODRUG TECHNOLOGY
July 13, 2004
METABASIS ANNOUNCES PUBLICATION
OF A NEW MOLECULAR MODELING TECHNOLOGY FOR IMPROVING DRUG DISCOVERY
AND OPTIMIZATION
June 25, 2004
METABASIS THERAPEUTICS HEPDIRECT™
LIVER TARGETING PRODRUG TECHNOLOGY DESCRIBED IN THE JOURNAL OF THE
AMERICAN CHEMICAL SOCIETY
NATURE Highlights HepDirect™ in News and Views
June 16, 2004
METABASIS THERAPEUTICS, INC. ANNOUNCES
PRICING OF INITIAL PUBLIC OFFERING
April 29, 2004
METABASIS THERAPEUTICS, INC. ANNOUNCES
APPOINTMENT OF DANIEL D. BURGESS, M.B.A. TO ITS BOARD OF DIRECTORS
April 16, 2004
METABASIS REPORTS THE EARNING OF
A MILESTONE PAYMENT BASED ON CONTINUED DEVELOPMENT OF REMOFOVIR
FOR THE TREATMENT OF HEPATITIS B
April 8, 2004
METABASIS THERAPEUTICS, INC. ANNOUNCES
RECEIPT OF A MILESTONE PAYMENT AFTER COMPLETION OF A SUCCESSFUL
PHASE IIA STUDY OF CS-917, A DRUG TO TREAT TYPE 2 DIABETES MELLITUS
February 3, 2004
METABASIS THERAPEUTICS, INC. FILES
REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING OF COMMON STOCK
January 13, 2004
METABASIS THERAPEUTICS AND MERCK
ANNOUNCE A COLLABORATION TO DEVELOP NEW TREATMENTS FOR HEPATITIS
C
October 28, 2003
METABASIS THERAPEUTICS, INC. COMPLETES
$24.9 MILLION PRIVATE FINANCING
October 16, 2003
METABASIS THERAPEUTICS, INC. AWARDED
A TWO YEAR, $2.4 MILLION PHASE II SBIR GRANT TO IDENTIFY HEPATITIS
C DRUGS
October 7, 2003
METABASIS THERAPEUTICS, INC. ANNOUNCES
THAT DR. SCOTT HECKER HAS JOINED AS EXECUTIVE DIRECTOR OF CHEMISTRY
September 26, 2003
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE COMPLETION OF A PHASE 2A STUDY OF CS-917, A DRUG TO TREAT TYPE
2 DIABETES MELLITUS
September 23, 2003
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE COMMENCEMENT OF CLINICAL TESTING OF MB7133 IN PATIENTS WITH
PRIMARY LIVER CANCER
April 3, 2003
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE COMMENCEMENT OF CLINICAL TESTING OF HEPAVIR B IN PATIENTS WITH
HEPATITIS B
January 3, 2003
METABASIS THERAPEUTICS, INC. TO
PRESENT AT J.P. MORGAN H&Q ANNUAL HEALTHCARE CONFERENCE
October 31, 2002
RIBAPHARM SUBMITS INVESTIGATIONAL
NEW DRUG APPLICATION FOR HEPAVIR B - A POTENTIAL NEW TREATMENT FOR
THE MORE THAN 1.25 MILLION AMERICANS CHRONICALLY INFECTED WITH THE
HEPATITIS B VIRUS
October 29, 2002
METABASIS THERAPEUTICS, INC. AND
SANKYO CO., LTD. SIGN OPTION AGREEMENT FOR DISCOVERY AND DEVELOPMENT
OF SECOND-GENERATION GLUCONEOGENESIS INHIBITOR FOR THE TREATMENT
OF DIABETES
August 7, 2002
METABASIS THERAPEUTICS, INC. ANNOUNCES
THAT DR. BILL FORBES HAS JOINED AS VICE PRESIDENT OF CLINICAL DEVELOPMENT
AND REGULATORY AFFAIRS
May 22, 2002
METABASIS THERAPEUTICS, INC. ANNOUNCES
THAT DR. ED BARACCHINI HAS JOINED AS VICE PRESIDENT OF BUSINESS
DEVELOPMENT
January 8, 2002
METABASIS THERAPEUTICS, INC. IS
ISSUED A US PATENT COVERING ITS HEPDIRECTTM TECHNOLOGY
December 11, 2001
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE FORMATION OF ITS SCIENTIFIC ADVISORY BOARD
November 1, 2001
METABASIS THERAPEUTICS, INC. AWARDED
SBIR GRANT TO DISCOVER NOVEL AGENTS TO TREAT LIVER FIBROSIS/CIRRHOSIS
October 23, 2001
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE COMPLETION OF A PRIVATE PLACEMENT OF STOCK RAISING $19.2 MILLION
October 2, 2001
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE SIGNING OF A DEVELOPMENT AND LICENSE AGREEMENT FOR ITS HepDirect™
HEPATITIS B THERAPEUTIC WITH ICN PHARMACEUTICALS, INC.
August 30, 2001
METABASIS THERAPEUTICS, INC. AWARDED
SBIR GRANT TO DISCOVER LIVER TARGETED HEPATITIS B PRODRUGS
August 1, 2001
METABASIS THERAPEUTICS, INC. ANNOUNCES
THE INITIATION OF HUMAN CLINICAL TRIALS FOR ITS DRUG TO TREAT DIABETES
MELLITUS
March 20, 2001
METABASIS THERAPEUTICS, INC. ANNOUNCES
EXTENSION OF ITS COLLABORATION WITH SANKYO TO DEVELOP NEW DRUGS
TO TREAT DIABETES MELLITUS
March 19, 2001
METABASIS THERAPEUTICS, INC. ANNOUNCES
THAT DR. DAVID LINEMEYER HAS JOINED AS HEAD OF BIOLOGY RESEARCH
September 19, 2000
METABASIS THERAPEUTICS, INC. ANNOUNCES
CHANGES TO ITS BOARD OF DIRECTORS
July 18, 2000
METABASIS THERAPEUTICS, INC. RAISES
$13 MILLION TO FUND DEVELOPMENT OF ITS LIVER RELATED DISEASE PROGRAM
February 10, 2000
METABASIS THERAPEUTICS, INC. ANNOUNCES
AN EXTENSION OF ITS COLLABORATION WITH SANKYO FOR DEVELOPMENT OF
A NEW DRUG TO TREAT DIABETES
|
|
|
|
